BIOVIT — Bio Vitos Pharma AB Share Price
Last trade - 00:00- SEK55.32m
- SEK52.25m
- SEK3.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.68 | ||
| Price to Tang. Book | 11.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.27% | ||
| Return on Equity | -44.5% | ||
| Operating Margin | -431.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | 0.31 | 1.12 | 1.32 | 3 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
Directors
- Fredrik Sjovall CHM (39)
- Annelie Brolinson CEO
- Robert Thoren CFO
- Bjorn Eriksson CTO
- Natasja Broman OTH
- Henrik Duhalde OTH
- Eva-Lotta Palm OTH
- Jenni Bjornulfson DRC (46)
- Anna Dalgaard DRC (38)
- Hjalmar Didrikson DRC (47)
- Torbjorn Koivisto DRC (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 14th, 2010
- Public Since
- March 15th, 2017
- No. of Employees
- 1
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 299,050,946
- Address
- Nanna Svartz vag 4, SOLNA, 171 65
- Web
- https://hemcheck.com/
- Phone
- +46 542022211
- Auditors
- BDO Goteborg AB
Upcoming Events for BIOVIT
Similar to BIOVIT
Acarix AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Aegirbio AB
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:04 UTC, shares in Bio Vitos Pharma AB are trading at SEK0.19. This share price information is delayed by 15 minutes.
Shares in Bio Vitos Pharma AB last closed at SEK0.19 and the price had moved by -56.06% over the past 365 days. In terms of relative price strength the Bio Vitos Pharma AB share price has underperformed the FTSE Global All Cap Index by -59.74% over the past year.
There is no consensus recommendation for this security.
Bio Vitos Pharma AB does not currently pay a dividend.
Bio Vitos Pharma AB does not currently pay a dividend.
Bio Vitos Pharma AB does not currently pay a dividend.
To buy shares in Bio Vitos Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.19, shares in Bio Vitos Pharma AB had a market capitalisation of SEK55.32m.
Here are the trading details for Bio Vitos Pharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BIOVIT
Based on an overall assessment of its quality, value and momentum Bio Vitos Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio Vitos Pharma AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +15.16%.
As of the last closing price of SEK0.19, shares in Bio Vitos Pharma AB were trading -17.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bio Vitos Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bio Vitos Pharma AB's management team is headed by:
- Fredrik Sjovall - CHM
- Annelie Brolinson - CEO
- Robert Thoren - CFO
- Bjorn Eriksson - CTO
- Natasja Broman - OTH
- Henrik Duhalde - OTH
- Eva-Lotta Palm - OTH
- Jenni Bjornulfson - DRC
- Anna Dalgaard - DRC
- Hjalmar Didrikson - DRC
- Torbjorn Koivisto - DRC